Denali Therapeutics Inc
DNLI
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.34B
Close$
$0.93
95.3% downside
Current Fair Value
95.3% downsideOvervalued by 95.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.34 Billion |
|---|---|
| Enterprise Value | $2.98 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.97 |
| Beta | 1 |
| Outstanding Shares | 186,636,978 |
Return
| Return on Equity | -54.86% |
|---|---|
| Return on Assets | -40.13% |
| Return on Invested Capital | -45.62% |
Valuation & Multiples
| P/E Ratio | -7.73 |
|---|---|
| PEG | 227.24 |
| Price to Sales | - |
| Price to Book Ratio | 4.92 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -5.65 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.73
Average shareholder expectationRevenue Estimate
$2.57 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
$25.74 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4934▲ 5.14% |
|---|---|
| Total Calls | 580,500▲ 701.80% |
| Total Puts | 286,400▲ 795.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 84.01%▼ 3.65% |
|---|---|
| Total Invested | $2.82B▲ 13.04% |
| Investors Holding | 279▲ 26.00% |
ESG Score
No data
About Denali Therapeutics Inc
CEO: Ryan Watts